An integrated view on monitoring and compensation for dynamic optical networks: from management to physical layer

A vertical perspective, ranging from management and routing to physical layer options, concerning dynamic network monitoring and compensation of impairments (M&C), is given. Feasibility, reliability, and performance improvements on reconfigurable transparent networks are expected to arise from the consolidated assessment of network management and control specifications, as a more accurate evaluation of available M&C techniques. In the network layer, physical parameters aware algorithms are foreseen to pursue reliable network performance. In the physical layer, some new M&C methods were developed and rating of the state-of-the-art reported in literature is given. Optical monitoring implementation and viability is discussed.Publicad

Rhythm measures with language-independent segmentation

We compare 15 measures of speech rhythm based on an automatic segmentation of speech into vowel-like and consonant-like regions. This allows us to apply identical segmentation criteria to all languages and to compute rhythm measures over a large corpus. It may also approximate more closely the segmentation available to pre-lexical infants, who apparently can discriminate between languages. We find that within-language variation is large and comparable to the between-languages differences we observed. We evaluate the success of different measures in separating languages and show that the efficiency of measures depends on the languages included in the corpus. Rhythm appears to be described by two dimensions and different published rhythm measures capture different aspects of it

PENTOXIFILLIN INTHETREATMENTOF RHEUMATOID ARTHRITIS

Objective. Assessment of the efficacy and tolerability of Pentoxifilline (PF) as compared with Methotrexate [ MT> and combination of MT+PF in patients with rheumatoid arthritis (RA). Material and methods. Controlled study of the efficacy and tolerability of MT, PF and their combination was done in 30 patients with active RA. 12 patients had PF in dose of 800-1200 mg/day, 11 - MT by 7.5-10 mg/week, 7 - MT 7.5 mg/week + PF 800-1200 mg/day. Assessment of the results was done in I, 3 and 6 months. Results. Patients taking MT demonstrated reliable improvement of the studied indices (10 out of 14). In the groups having PF and PF+MT there were no reliable improvement in any of the parameters under study. Conclusion. The obtained results testify to inefficacy of PF during the treatment of RA patients. Combined indication of MT and PF has no advantages as compared with monotherapy by MT

Antithrombotics in intracerebral hemorrhage in the era of novel agents and antidotes: A review

Background Intracerebral hemorrhage (ICH)1 is characterized by the pathological accumulation of blood within the brain parenchyma, most commonly associated with hypertension, arteriovenous malformations, or trauma. However, it can also present in patients receiving antithrombotic drugs, either anticoagulants such as acenocoumarol/warfarin—novel oral anticoagulants or antiplatelets, for the prevention and treatment of thromboembolic disease. Objective The purpose of this review is to present current bibliographic data regarding ICH irrespective of the cause, as well as post-hemorrhage use of antithrombotic agents. Moreover, this review attempts to provide guidelines concerning the termination, inversion, and of course resumption of antithrombotic therapy. Methods and Materials We reviewed the most recently presented available data for patients who dealt with intracerebral hemorrhagic events while on antithrombotic agents (due to atrial fibrillation, prosthetic mechanical valves or recent/recurrent deep vein thrombosis). Furthermore, we examined and compared the thromboembolic risk, the bleeding risk, as well as the re-bleeding risk in two groups: Patients receiving antithrombotic therapy versus patients not on antithrombotic therapy. Conclusion Antithrombotic therapy is of great importance when indicated, though it does not come without crucial side-effects, such as ICH. Optimal timing of withdrawal, reversal, and resumption of antithrombotic treatment should be determined by a multidisciplinary team consisting of a stroke specialist, a cardiologist, and a neurosurgeon, who will individually approach the needs and risks of each patient. © 2020 Dimitrios Giakoumettis et al